Takeda Pharmaceutical (TAK) Total Debt (2018 - 2026)

Takeda Pharmaceutical's Total Debt history runs 9 years deep, the most recent figure standing at $28.8 billion for Q1 2026.

• On a quarterly basis, Total Debt fell 2.81% year-over-year to $28.8 billion in Q1 2026; TTM through Mar 2026 was $28.8 billion, a 2.81% decrease from a year earlier, with the FY2026 full-year figure at $30.0 billion, up 1.1% from the prior year.
• Total Debt advanced to $28.8 billion in Q1 2026 per TAK's latest filing, from $27.7 billion in the prior quarter.
• Across five years, Total Debt topped out at $37.4 billion in Q1 2022 and bottomed at $6.6 billion in Q1 2023.
• The 5-year median for Total Debt is $29.6 billion (2025), against an average of $27.7 billion.
• Across the five-year window, Total Debt soared 416.87% in 2022 and slumped 82.33% in 2023, its largest moves.
• Year by year, Total Debt stood at $27.7 billion in 2022, then grew by 4.83% to $29.0 billion in 2023, then rose by 6.53% to $30.9 billion in 2024, then slipped by 10.34% to $27.7 billion in 2025, then advanced by 3.66% to $28.8 billion in 2026.
• Per Business Quant, the three latest TAK Total Debt figures stand at $28.8 billion (Q1 2026), $27.7 billion (Q4 2025), and $29.5 billion (Q3 2025).